{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:51:50Z","timestamp":1787579510644,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary sarcomatoid carcinoma (PSC) is a unique subtype of non-small cell lung cancer (NSCLC) with a high degree of malignancy and poor therapeutic effects. With the widespread use of immune checkpoint inhibitors (ICIs) in recent years, few studies have reported that immunotherapy is effective against PSC. As a multi-target anti-vascular targeting agent, anlotinib showed a better anti-tumor effect in various cancer species. The paper reported the therapeutic and side effects of pembrolizumab combined with anlotinib in a patient with advanced PSC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>This is a 73 year old female patient who underwent thoracoscopy right upper lobectomy and was diagnosed as locally advanced PSC. However, the patient experienced tumor recurrence and metastasis 7 weeks after surgery and was unable to tolerate chemoradiotherapy. Moreover, she detected TP53 mutation and found that tumor mutation burden (TMB) and PD-L1 were high expression. Therefore, the patient received pembrolizumab combined with anlotinib treatment. After 15 cycles of treatment, the tumor significantly shrank with no tumor activity. The evaluation of tumor efficacy is partial response (PR). During the treatment period, she experienced one-degree thyroid-stimulating hormone elevation and two-degree hand-foot syndrome. Pembrolizumab and anlotinib was continued for two years as a maintenance treatment. The patient had a good quality of life and no disease progression was observed. Currently, the patient is still alive without tumor progression and has overall survival exceeding 45 months and toxic side effects were tolerable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combining ICIs and anti-angiogenic targeted therapy has brought new hope in treating advanced PSC. Additionally, TMB and PD-L1 expression could be potential predictive biomarkers of the efficacy in advanced PSC with immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1274937","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:15:15Z","timestamp":1698052515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Shugui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanlian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.11.016","article-title":"Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base","volume":"18","author":"Steuer","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"15","author":"Domblides","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2020.02.071","article-title":"Pulmonary sarcomatoid carcinoma: experience from SEER database and Shanghai pulmonary hospital","volume":"110","author":"Sun","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezx417","article-title":"Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database","volume":"53","author":"Rahouma","year":"2018","journal-title":"Eur J cardio-thoracic Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2016.08.114","article-title":"Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: A multicenter analysis","volume":"103","author":"Lococo","year":"2017","journal-title":"Ann Thorac surgery."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2015.10.009","article-title":"Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma","volume":"76","author":"Gu","year":"2015","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.12.008","article-title":"Sarcomatoid carcinoma of the lung: the mayo clinic experience in 127 patients","volume":"19","author":"Maneenil","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1038\/s41467-020-18702-3","article-title":"Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2021.01.006","article-title":"The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients","volume":"153","author":"Zhou","year":"2021","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death disease."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S257052","article-title":"Association of TP53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer","volume":"13","author":"Fang","year":"2020","journal-title":"OncoTargets Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-019-01374-5","article-title":"(18)F-FDG PET\/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings","volume":"33","author":"Wu","year":"2019","journal-title":"Ann Nucl Med"},{"key":"B21","article-title":"Pulmonary Sarcomatoid carcinoma: a surgical diagnosis and prognostic factors","volume":"97","author":"Smadhi","year":"2019","journal-title":"La Tunisie medicale"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101824","DOI":"10.1016\/j.suronc.2022.101824","article-title":"Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma: A systematic review and meta-analysis","volume":"44","author":"Zombori-T\u00f3th","year":"2022","journal-title":"Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.jtcvs.2021.01.081","article-title":"Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database","volume":"163","author":"Abdallah","year":"2022","journal-title":"J Thorac Cardiovasc surgery."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.04.084","article-title":"Personal experience in surgical management of pulmonary pleomorphic carcinoma","volume":"78","author":"Raveglia","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3000605221128092","DOI":"10.1177\/03000605221128092","article-title":"Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment","volume":"50","author":"Gong","year":"2022","journal-title":"J Int Med Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet (London England)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13460","article-title":"Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma","volume":"17","author":"A\u011fa\u00e7k\u0131ran","year":"2021","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.029","article-title":"Outstanding clinical efficacy of PD-1\/PD-L1 inhibitors for pulmonary pleomorphic carcinoma","volume":"132","author":"Lee","year":"2020","journal-title":"Eur J Cancer (Oxford Engl 1990)."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2022_220617N644","article-title":"The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study","volume":"69","author":"Wei","year":"2022","journal-title":"Neoplasma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01454-6","article-title":"Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas","volume":"24","author":"Liang","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S169074","article-title":"CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manage Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003773","article-title":"Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers","volume":"9","author":"Hu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0163","article-title":"TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma","volume":"24","author":"Biton","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001129","article-title":"Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model","volume":"28","author":"Taurin","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-019-0383-7","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (London England)."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer","volume":"69","author":"Yang","year":"2020","journal-title":"Cancer Immunol Immunother CII."},{"key":"B47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14907","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice","volume":"14","author":"Inomata","year":"2023","journal-title":"Thorac cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956982","article-title":"The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma","volume":"13","author":"Qian","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1274937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:15:19Z","timestamp":1698052519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1274937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2023.1274937"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1274937","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"1274937"}}